

US Bioservices has Pfizer's XALKORI® in stock – now FDA approved to treat metastatic non-small cell lung cancer

The U.S. Food and Drug Administration recently approved the expanded use of Pfizer's XALKORI® (crizotinib) for the treatment of metastatic non-small cell lung cancer (NSCLC), when tumors have an ROS-1 gene alteration. The FDA also granted XALKORI® breakthrough therapy designation and priority review status.

XALKORI® is an oral medication that blocks the activity of the ROS-1 protein in tumors that have ROS-1 gene alterations, which may prevent NSCLC cells from growing and spreading.

US Bioservices has been selected as an authorized specialty pharmacy in a limited distribution network for XALKORI®. Fax prescriptions to (888) 899-0067.

At a Glance

- Recommended Dose: 250 mg orally twice daily
- Formulation: 250 mg and 200 mg hard gel cap
- NDC: 00698-140-20
- Packaging: 60 count bottle

More Information

- Xalkori Website
www.xalkori.com
- Prescribing Information
<http://labeling.pfizer.com/ShowLabeling.aspx?id=676>
- FDA Press Release
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm>